XUHC:XETRA:XETRA-Xtrackers MSCI USA Health Care UCITS ETF 1D EUR (EUR)

ETF | Others |

Last Closing

USD 56.97

Change

-0.09 (-0.16)%

Market Cap

USD 0.85B

Volume

2.68K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.26 (+0.50%)

USD 445.28B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.08 (+0.45%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.38 (+1.37%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.13 (+0.46%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.15 (+0.58%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.25 (+0.53%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

+0.52 (+0.36%)

USD 98.84B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.25 (+0.48%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+1.72 (+1.64%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.86 (+0.30%)

USD 80.38B

ETFs Containing XUHC:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.07% 86% B+ 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.07% 86% B+ 81% B-
Trailing 12 Months  
Capital Gain 8.31% 42% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.31% 41% F 44% F
Trailing 5 Years  
Capital Gain 57.68% 73% C 74% C
Dividend Return 5.98% 35% F 27% F
Total Return 63.66% 75% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 11.09% 68% D+ 67% D+
Dividend Return 11.16% 67% D+ 66% D+
Total Return 0.07% 10% F 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 10.62% 60% D- 68% D+
Risk Adjusted Return 105.13% 91% A- 92% A
Market Capitalization 0.85B 75% C 66% D+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.